SAB Biotherapeutics SAB-142 Shows C-Peptide Preservation in Type 1 Diabetes Phase 1 Trial

Key Takeaways

• All 4 Type 1 diabetes patients receiving SAB-142 demonstrated C-peptide preservation, indicating maintained insulin production
• Three of four participants showed ‘super responder’ profiles with T cell exhaustion, suggesting strong immune modulation
• Patients experienced improved glycemic control, potentially reducing long-term diabetes complications

---

SAB Biotherapeutics (Nasdaq: SABS) reported promising Phase 1 clinical trial results for SAB-142, showing C-peptide preservation in all Type 1 diabetes patients treated with the experimental therapy.

The clinical-stage biopharmaceutical company presented additional data from its SAB-142 Phase 1 trial at the International Diabetes Summit (IDS) 2026, demonstrating the potential of its fully human anti-thymocyte immunoglobulin (hATG) approach for treating established autoimmune Type 1 diabetes.

Clinical Results Show Promise

In the small cohort of adult patients with established Type 1 diabetes, SAB-142 demonstrated consistent efficacy across key measures. All four participants maintained C-peptide levels, a critical biomarker indicating the pancreas continues producing insulin. C-peptide preservation is particularly significant in Type 1 diabetes, where autoimmune destruction typically eliminates insulin-producing beta cells.

Three participants exhibited what researchers termed a “super responder profile,” characterized by T cell exhaustion - a mechanism that may help control the autoimmune attack on pancreatic beta cells. This immune modulation represents a potential breakthrough in treating the underlying cause of Type 1 diabetes rather than just managing symptoms.

IntelligenceRegulatory Impact▾

EMA and MHRA are the agencies to watch. Regulatory relevance reads medium for pharmaceutical intelligence. Teams should track submission types, designations, and guidance shifts that could move approval timelines.

Improved Metabolic Control

Beyond biomarker improvements, patients receiving SAB-142 showed enhanced glycemic control, suggesting real-world benefits for diabetes management. Better glucose control typically translates to reduced risk of long-term complications including cardiovascular disease, kidney damage, and neuropathy.

IntelligenceCompetitive Intelligence▾

Competitive pressure is low. Watch which sponsors move first. Benchmark pipeline positioning, differentiation, and partnership scouting against the signals in this story.

Market and Clinical Implications

The results position SAB-142 as a potential disease-modifying therapy for Type 1 diabetes, a market currently dominated by insulin replacement therapies. While the Phase 1 trial involved only four patients, the consistent positive responses across all participants provide encouraging signals for larger clinical studies.

SAB Biotherapeutics’ hATG approach represents a novel strategy in autoimmune disease treatment, potentially offering advantages over existing immunosuppressive therapies through more targeted immune modulation.

The company has not yet announced timeline details for Phase 2 trials, but these preliminary results may accelerate development discussions with regulatory authorities.

---

Frequently Asked Questions

What does C-peptide preservation mean for Type 1 diabetes patients?

C-peptide preservation indicates that insulin-producing beta cells in the pancreas remain functional, potentially reducing insulin dependency and improving long-term diabetes management compared to complete beta cell loss.

When will SAB-142 be available for Type 1 diabetes treatment?

SAB-142 is currently in Phase 1 trials. The drug would need to complete Phase 2 and Phase 3 trials and receive FDA approval, which typically takes several years from current stage.

How does SAB-142 differ from current Type 1 diabetes treatments?

Unlike insulin therapy which replaces missing hormone, SAB-142 aims to modify the autoimmune disease process itself, potentially preserving natural insulin production and addressing the root cause of Type 1 diabetes.

Related coverage

• New EU Template for Clinical Trial Recruitment and Informed Consent: What Pharma Teams Need to Know
• Health News Round Up: Diabetes, Vaping, and Biologics – What Pharma Teams Need to Know
• Myasthenia Gravis Clinical Trial Pipeline Expands as 25+ Companies Race to Redefine Myasthenia Gravis Treatment Landscape | DelveInsight — regulatory updates